Table 1.
Clinical and pathological data of group 1 and group 2 patients
| Parameter | Group 1 (n = 28) | Group 2 (n = 26) | ||
|---|---|---|---|---|
| Primary HCC | Site | Exophitic | 39.3% | 30.8% |
| Subcapsular | 7.1% | 11.5% | ||
| Deep | 53.6% | 57.7% | ||
| Primary treatment | Resection | 82.1% | 100% | |
| PEI/RFA | 17.9% | 0% | ||
| Tumor violation | Needle tract injury | 53.6% | 7.7 | |
| Spontaneous HCC rupture | 14.3% | 0% | ||
| TACE | 3.6% | 0% | ||
| No violation | 28.6% | 92.3% | ||
| Number of PPL/extrahepatic lesions | Single | 53.6% | 0% | |
| Multiple | 46.4% | 100% | ||
| Intrahepatic-associated recurrences | 60.7% | 53.8% | ||
| Delay of appearance of recurrence after the primary treatment (months) | After resection | Mean | 20 | 13 |
| Range | 1-45 | 2-44 | ||
| After PB/PEI/RFA | Mean | 15 | – | |
| Range | 4-23 | – | ||
HCC, hepatocellular carcinoma; PB, percutaneous biopsy; PEI, percutaneous ethanol injection; PPL, parietal and/or peritoneal localization; RFA, radiofrequency ablation; TACE, transarterial chemoembolization.